What's Happening?
CereVasc, Inc., a medical device company based in Massachusetts, has completed patient enrollment for its STRIDE pivotal trial. This trial evaluates the eShunt System, a minimally invasive treatment for normal pressure hydrocephalus (NPH). The eShunt System is designed
to offer an alternative to the traditional ventriculo-peritoneal (VP) shunt, which has been the standard treatment for over 60 years. The trial, conducted at 32 clinical sites, aims to compare the eShunt System's effectiveness against the VP shunt. With enrollment complete, the trial will proceed with treatment and follow-up activities, moving towards FDA Premarket Approval (PMA).
Why It's Important?
The completion of enrollment in the STRIDE trial marks a significant step in developing a new treatment for NPH, a condition affecting approximately 800,000 people in the U.S. The current standard treatment involves invasive brain surgery, which may not be suitable for all patients, especially the elderly or those with comorbidities. The eShunt System offers a less invasive option, potentially expanding treatment accessibility and improving patient outcomes. Successful trial results could lead to FDA approval, providing a new therapeutic option for NPH patients and potentially transforming the treatment landscape for this condition.
What's Next?
Following the completion of patient treatment and follow-up, CereVasc will analyze the trial data to support its PMA submission to the FDA. If approved, the eShunt System could become the first new treatment for NPH in over six decades. The company will continue to focus on advancing this minimally invasive option, with the potential to significantly impact the lives of those living with NPH. The medical community and stakeholders will be closely monitoring the trial's outcomes and the subsequent regulatory process.
